B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids.
Ferraccioli
GianFranco
G
Gremese
Elisa
E
De Santis
Maria
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000473:pathology*; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000276:immunology / Q000628:therapy*; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007937:Leukapheresis / Q000379:methods; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology / Q000628:therapy*; D000069283:Rituximab; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab; D016572:Cyclosporine